Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA limits use of Stryker's troubled Wingspan brain stent, but stops short of withdrawal

This article was originally published in Clinica

Executive Summary

The US FDA has limited the patient population who can receive Stryker's brain stent Wingspan, on the back of safety concerns that have dogged the device since last year. However, the news could have been worse for Stryker; earlier this year, an FDA advisory panel concluded that the stent is no more effective than drug therapy at preventing stroke, leading to speculation that Wingspan might be withdrawn from the market altogether (www.clinica.co.uk, 26 March 2012).

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT099235

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel